Cogent Biosciences, Inc. COGT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s EPS (diluted)?
- Cogent Biosciences, Inc. (COGT) reported EPS (diluted) of -$0.53 in Q1 2026.
- How has Cogent Biosciences, Inc.'s EPS (diluted) changed year-over-year?
- Cogent Biosciences, Inc.'s EPS (diluted) decreased by 1.9% year-over-year, from -$0.52 to -$0.53.
- What is the long-term trend for Cogent Biosciences, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Cogent Biosciences, Inc.'s EPS (diluted) has grown at a 3.7% compound annual growth rate (CAGR), from -$1.87 to -$2.16.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.